Last updated: 11/03/2018 00:19:35
An open label, multi centre phase IV study of Adefovir Dipivoxil in Korean patients with chronic hepatitis B (CHB)NA
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An open label, multicenter phase IV study of adefovir dipivoxil in Korean patients with chronic hepatitis B (CHB)
Trial description: Objective(s)The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease. The secondary study objectives are to assess the antiviral effect, clinical benefit and safety of 52 weeks of adefovir dipivoxil treatment.Endpoint(s)The primary efficacy endpoint is “Mean log10 reduction in serum HBV DNA level from baseline to Week 12”.The secondary efficacy endpoints include (a) the proportion of patients achieving serum ALT normalization at Week 52, (b) other assessments of antiviral effects (the proportion of patients achieving HBV DNA no less than 300 copies per mL at Week 52), (c)HBeAg loss, HBeAg seroconversion, HBsAg loss and HBsAg seroconversion, (d)the proportion of patients achieving serum ALT normalization at Week 12.Study DesignThis is an open label, multi centre phase IV study for Korean patients with chronic hepatitis B and compensated liver disease, assessing the antiviral effect of 12 weeks treatment of Adefovir dipivoxil as a primary objective and antiviral effect, clinical benefit and safety of 52 weeks treatment as secondary objectives.Patients will be screened for eligibility criteria and the baseline visit for the treatment initiation should occur no more than 4 weeks after screening. Total treatment period will be 52 weeks and patients will return to the clinic for assessments as scheduled during treatment period. After the 52 week study period, it is likely that the patient will benefit from continued treatment with commercial adefovir. If in the investigator's clinical judgement this is the case, the investigator should ensure that a routine prescription is available in a timely manner, and that no unnecessary interruption in treatment occurs.Study PopulationA minimum of 100 male or female Korean patients more than 18 years of age with HBeAg positive chronic hepatitis B and compensated liver disease who meet the eligibility criteria will be enrolled.Study Assessments and Procedures Potential patients will be screened prior to study entry and eligible patients who have given their consent will have further baseline assessments. Following the screening, the first doses of study medications will be given at baseline and patients will return to the clinic for assessment as scheduled during treatment period. Patients who discontinue treatment prematurely will be followed up every 4 weeks for 12 weeks following the withdrawal visit. The following key assessment and or measurement will be made at one or more visits during the study. (See section 14.1 Appendix 1. Time and event schedule):• Pregnancy test (females of child-bearing potential only)• Haematology and serum chemistry profile including prothrombin time(PT) and AFP • HBV DNA (Roche COBAS AMPLICOR HBV MONITOR Test, LLOD 300 copies per ml)• Hepatitis B markers: HBeAg(Anti HBe will be tested if HBeAg is negative), HBsAg(Anti HBs will be tested if HBsAg is negative)Investigational Product(s)Adefovir dipivoxil 10mg tablets will be supplied by GlaxoSmithKline and presented as a white to off white, round tablets, packaged in the bottle containing 30 tablets
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Mean log 10 reduction in serum Hepatitis B virus (HBV), deoxyribonucleic acid (DNA) level from baseline to Week 12
Timeframe: Baseline (Day 1) and Week 12
Secondary outcomes:
Number of participants achieving alanine aminotransferase (ALT) normalization at Week 52
Timeframe: At week 52
Number of participants achieving virological response at week 52
Timeframe: At Week 52
HBV DNA levels at each collection timepoint through Week 52
Timeframe: Week 4, week 8, week 12, week 20, week 28, week 36, week 44 and week 52
Number of participants with hepatitis B e viral protein (HBeAg) loss, HBeAg seroconversion, hepatitis B virus surface antigen (HBsAg) loss and HBsAg seroconversion at Week 52
Timeframe: Week 52
Number of participants achieving ALT normalization at Week 12
Timeframe: at Week 12
Number of participants with adverse events (AE) and serious adverse events (SAEs)
Timeframe: From treatment initiation (Week 0) to follow-up (up to 52 weeks)
Number of participants with shift from baseline hematology parameters at week 12 and week 52
Timeframe: Baseline (Day 1), Week 12 and Week 52
Number of participants with shift from baseline clinical chemistry parameters at week 12 and week 52
Timeframe: Baseline (Day 1), Week 12 and Week 52
Mean log 10 reduction in serum HBV DNA level from baseline to Week 52
Timeframe: Baseline (Day 1) and Week 52
Interventions:
Enrollment:
104
Observational study model:
Not applicable
Primary completion date:
2006-28-04
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Hepatitis B, Chronic
Product
adefovir
Collaborators
GSK
Study date(s)
December 2004 to April 2006
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- 1. Age more than 18 years
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- 1. Use of immunosuppressive therapy requiring use of more than 5mg of prednisone(or equivalent) per day, immunomodulatory therapy (including interferon or thymosin ) or systemic cytotoxic agents within previous 6 months or during the study
Inclusion and exclusion criteria
Inclusion criteria:
- A subject will be eligible for inclusion in this study only if all of the following criteria apply: 1. Age more than 18 years 2. HBV Serology Presence of HBsAg for at least 6 months Presence of HBeAg at the time of screening Positive HBV DNA plasma assay with screening value at the time of screening 4. Evidence of at least one elevated serum alanine amonotransferase (ALT) levels greater than 2 times (inclusive) the upper limit of the normal range (ULN) in the previous 6 months. serum ALT levels greater than 2 times (inclusive) the ULN at screening visit. 5. Availability and willingness of subject to provide written informed consent.
Exclusion criteria:
- A subject will not be eligible for inclusion in this study if any of the following criteria apply: 1. Use of immunosuppressive therapy requiring use of more than 5mg of prednisone(or equivalent) per day, immunomodulatory therapy (including interferon or thymosin ) or systemic cytotoxic agents within previous 6 months or during the study 2. Previous or current lamivudine or adefovir dipivoxil therapy or antiviral therapy with agents demonstrating potential anti-HBV activity 3. Clinical signs of decompensated liver disease at screening according to the protocol 4. Serum creatinine over 1.5mg per dL 5. Alanine aminotransferase (ALT) over 10 times ULN at screening or history of acute exacerbation leading to transient decompensation 6. Serum Amylase and/or lipase over 2 times ULN 7. Inadequate haematological function 8. Anti-HBe or Anti-HBs positive subjects 9. Hepatocellular carcinoma as evidenced by the protocol 10. Documented evidence of active liver disease 11. Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include any uncontrolled clinically significant renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders or cancer. 12. Active alcohol or drug abuse or history of alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results. 13. Planned for liver transplantation or previous liver transplantation 14. Receipt of any investigational drug within within 3 months prior to screening. 15. Therapy with nephrotoxic drugs or competitors of renal excretion within 2 months prior to study screening or the expectation that patient will receive any of these during the course of the study. 16. History of hypersensitivity to nucleoside and/or nucleotide analogues. 17. Inability to comply with study requirements as determined by the study investigator.
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2006-28-04
Actual study completion date
2006-28-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website